Drug Trial Radar · NCT00099359
Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission
Last checked: Nov 19, 2026Latest source record: Dec 4, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,735
Actual
Start
Feb 2004
Primary completion
Feb 2011
Study completion Feb 2011
Sponsor
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
- Sponsor type
- NIH
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Dec 13, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, up to 2 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Giving anti-HIV medications to babies born of HIV positive mothers right after birth can lower the babies' risk of contracting HIV. This study will assess the safety and efficacy of two different combinations of anti-HIV medications compared to a one drug standard regimen in preventing mother to baby transmission. The one drug standard treatment and two combinations to be studied are: 1) zidovudine, 2) zidovudine/nevirapine and 3) zidovudine/lamivudine/nelfinavir.
Conditions
- Disease Transmission, Vertical
- Vertical Human Immunodeficiency Virus Transmission
- HIV Infections
Interventions
ZidovudineDrug
Given for 6 weeks. 12mg PO BID if birthweight (BW) \> 2000 grams 8 mg PO BID if BW \< 2000 grams
Nevirapine (NVP)Drug
Standard of Care (Zidovudine) plus NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose : 12 mg PO per dose if BW \> 2000 grams, 8 mg PO per dose if BW \< 2000 grams
Epivir (3TC)Drug
Stand of care (Zidovudine) plus 3TC, given for 2 weeks: 6 mg po bid if BW \> 2000 grams 4 mg po bid if BW \< 2000 grams AND NFV, given for 2 weeks: 200 mg po bid if BW \> 3000 grams 150 mg po bid if BW \> 2,000 - 3000 grams 100 mg PO BID if BW \< 2000 grams
Nelfinavir (NFV)Drug
200 mg BID if birth weight (BW) \> 3000 grams for 2 weeks;150 mg BID if BW \> 2000-3000 grams for 2 weeks; 100 mg BID BW \</= 2000 grams for 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Infant HIV Infection StatusTime frame: 3 months
- Participants With Serious Adverse EventsTime frame: through age 6 months.
Locations
17 sites in 5 countries. Site status is shown where the registry gives one.
Miller Children's Hospital
Long Beach, California
University of FL
Gainesville, Florida
University of FL-HSC
Jacksonville, Florida
University Medical and Dental School of NJ-Newark Campus
Newark, New Jersey
Texas Childrens Hospital
Houston, Texas
Hospital I. G. A. Dr. Diego Paroissien
Buenos Aires, Argentina
Hospital dos Servidores do Estado (HSE)
Rio de Janeiro, Brazil
Hospital Geral de Novo Iguacu
Rio de Janeiro, Brazil
5088 - Universidade Federal de Sao Paulo (UFSP)
São Paulo, Brazil
Federal University of Minas Gerais (UFMG)
Belo Horizonte, Minas Gerais, Brazil
Universidade de Sao Paulo (USP) , MD
São Paulo, Ribeirão Preto, Brazil
Hospital Fêmina S.A. Unidade Perinatal de Transmissão Vertical
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Santa Casa (HSC)
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceicao (GHC)
Porto Alegre, Rio Grande do Sul, Brazil
San Juan Hospital
San Juan, Puerto Rico
Tygerberg Hospital
Cape Town, South Africa
Chris Hani Baragwanath Hospital
Johannesburg, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.